Theralase Technologies Inc. (CVE:TLT – Get Free Report)’s share price dropped 1.6% during mid-day trading on Friday . The stock traded as low as C$0.29 and last traded at C$0.30. Approximately 41,605 shares were traded during trading, a decline of 70% from the average daily volume of 138,317 shares. The stock had previously closed at C$0.31.
Theralase Technologies Stock Down 1.6 %
The company has a current ratio of 1.21, a quick ratio of 3.40 and a debt-to-equity ratio of 20.58. The firm has a market cap of C$73.66 million, a PE ratio of -15.00 and a beta of 1.36. The business’s 50-day simple moving average is C$0.27 and its 200 day simple moving average is C$0.22.
Theralase Technologies Company Profile
Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.
Featured Articles
- Five stocks we like better than Theralase Technologies
- Top Stocks Investing in 5G Technology
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- The Most Important Warren Buffett Stock for Investors: His Own
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- How to Evaluate a Stock Before BuyingÂ
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
